Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals seeks approval for obesity treatment trial in New Zealand
Clinical Trials Arena
Tue, 09/24/24 - 11:51 am
Arrowhead Pharmaceuticals
clinical trials
ARO-INHBE
RNAi
obesity
New Zealand
Arrowhead’s RNAi therapeutic plozasiran shows promise in familial chylomicronaemia syndrome
PM Live
Tue, 09/3/24 - 11:23 am
Arrowhead Pharmaceuticals
RNAi
familial chylomicronemia syndrome
plozasiran
After clearing out heart disease drug, Arrowhead maps out obesity development plans
Fierce Biotech
Wed, 08/14/24 - 10:41 pm
Arrowhead Pharmaceuticals
RNAi
R&D
obesity
heart disease
Arrowhead axes heart disease drug, goes all in on another as pipeline progress drives costs up
Fierce Biotech
Wed, 06/26/24 - 10:05 am
Arrowhead Pharmaceuticals
RNAi
zodasiran
plozasiran
cardiovascular disease
Arrowhead's much-anticipated cholesterol drug hits the mark again in phase 2 hyperlipidemia trial
Fierce Biotech
Thu, 05/30/24 - 11:04 am
Arrowhead Pharmaceuticals
clinical trials
hyperlipidemia
plozasiran
Arrowhead's plozasiran could reach $700M-plus in sales by 2032, meet major unmet need in dyslipidemia: GlobalData
Fierce Pharma
Tue, 04/16/24 - 10:05 pm
Arrowhead Pharmaceuticals
clinical trials
RNAi
plozasiran
dyslipidemia
Arrowhead axes assets, but spares staff, to save $100M a year in refocus on core areas
Fierce Biotech
Wed, 02/7/24 - 11:21 am
Arrowhead Pharmaceuticals
RNAi
2 Biotech Stocks That Could Soar by 130% and 92%, According to Wall Street
Motley Fool
Tue, 04/4/23 - 11:25 pm
Arrowhead Pharmaceuticals
Seres Therapeutics
Biotech heads towards big catalysts
EP Vantage
Tue, 03/28/23 - 10:24 am
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
FDA grants fast track designation to Arrowhead Pharmaceuticals’ ARO-APOC3 to reduce triglycerides
Pharmaceutical Business Review
Tue, 03/21/23 - 09:57 am
Arrowhead Pharmaceuticals
ARO-APOC3
triglycerides
familial chylomicronemia syndrome
fast track
FDA
Spotlight – What is next in Nash
EP Vantage
Fri, 03/3/23 - 10:02 am
NASH
clinical trials
89Bio
Arrowhead Pharmaceuticals
Can-Fite BioPharma
Ewopharma
Hepagene Therapeutics
JNJ
Ligand Pharmaceuticals
Madrigal Pharmaceuticals
Merck
NGM Biopharmaceuticals
NorthSea Therapeutics
Novartis
Sagimet Biosciences
Terns Pharmaceuticals
Viking Therapeutics
Spotlight – Cystic fibrosis developers take a deep breath
EP Vantage
Mon, 02/27/23 - 10:02 am
cystic fibrosis
MRNA
Vertex Pharmaceuticals
4D Molecular Therapeutics
Arcturus Therapeutics
Arrowhead Pharmaceuticals
Boehringer Ingelheim
Eloxx Pharmaceuticals
Krystal Biotech
Moderna Therapeutics
Oxford BioMedica
ReCode Therapeutics
SpliSense
Sumitomo Pharmaceuticals
Tessera Therapeutics
Janssen Returns Phase I NASH Candidate to Arrowhead
BioSpace
Wed, 02/15/23 - 06:08 pm
JNJ
Janssen
RNAi
Arrowhead Pharmaceuticals
NASH
JPM Day 1: Highlights
BioSpace
Mon, 01/9/23 - 11:01 pm
JPMHC 2023
Sarepta Therapeutics
Biomarin
Alnylam
JNJ
Arrowhead Pharmaceuticals
Novartis
Bristol Myers Squibb
Biotech’s key upcoming clinical results
EP Vantage
Tue, 12/20/22 - 10:27 am
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Arrowhead Gets $250M in Royalty Deal for Cardio Drug Heading to Phase 3
MedCity News
Wed, 11/9/22 - 11:30 pm
Amgen
Arrowhead Pharmaceuticals
olpasiran
heart disease
Biotech’s near-term key catalysts
EP Vantage
Thu, 09/29/22 - 09:45 am
Biogen
Eisai
Alzheimer's disease
Arrowhead Pharmaceuticals
Takeda
RNAi
Madrigal
NASH
Ascendis
FDA
Ascletis, Takeda, Arrowhead & More Present New Findings at EASL Liver Conference
BioSpace
Tue, 06/28/22 - 10:49 am
EASL
liver disease
Ascletis
Takeda
Arrowhead Pharmaceuticals
GlaxoSmithKline takes aim at NASH, penning a $1B pact with RNAi biotech Arrowhead
Fierce Biotech
Mon, 11/22/21 - 10:19 pm
GSK
Arrowhead Pharmaceuticals
NASH
RNAi
Arrowhead rocked by animal tox issues again, hitting the pause button on RNAi study in cystic fibrosis
Endpoints
Fri, 07/2/21 - 11:04 am
Arrowhead Pharmaceuticals
RNAi
animal research
cystic fibrosis

Pages